• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Survey: U.S. M&A activity likely to increase

Survey: U.S. M&A activity likely to increase

July 14, 2011
CenterWatch Staff

U.S. drug makers are likely to step up their acquisition activities in a bid to find new therapies, and they have the cash to do so, according to a survey by KPMG reported by Pharma-Times.

The consultants polled 100 U.S. senior pharmaceutical executives, of which 83% said it is likely their companies will be involved in a merger or acquisition as a buyer or seller in the next two years.

Of respondents, 41% believed the largest area of spending in the next year would be for acquisitions, followed by new products and services at 38%, and R&D at 38%.

A strategic acquisition was cited as the highest priority investment area by 41% of executives surveyed, followed by expansion into new markets at 22%.

Top issues facing their companies included patent expirations of key therapies and generic competition at 58%, followed by increasing regulation and enforcement (45%) and lack of new products in the pipeline (34%).

More than 75% of executives said their organizations had significant cash on hand, and 50% expect to increase capital spending over the next year. More than a third said investment was already underway, while an additional 36% said spending would be made before the end of the first quarter of 2012.

When asked what single initiative their company's management would spend the most energy on in the next two years, 23% said investing in organic growth, followed by 16% who believe cost reduction initiatives are the priority. Some 16% say improving operation processes and related technology will be the main focus.

When asked about the timing of a full recovery, 31% said by the end of next year, 27% believe it will not happen until the end of 2013, and 27% say the end of 2014. In terms of headcount, 41% of executives said they plan to add personnel next year, while 23% "never expect hiring to return to pre-recession levels."

"The good news is companies have cash to invest in or acquire new medicine breakthroughs, or markets and customers to drive some growth," said David Blumberg, KPMG national advisory pharmaceutical sector lead partner.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing